a2 National Symposium

DanielBelsky, PhD, is an Associate Professor of Epidemiology in the Mailman School ofPublic Health (Department of Epidemiology and Robert N Butler Columbia AgingCenter) at Columbia University Irving Medical Center (CUIMC).

In hisresearch, Dr. Belsky aims to reduce social inequalities in aging outcomes inthe US and elsewhere. His research sits at the intersection of public health,population & behavioral science, and genomics. His studies seek tounderstand how genes and environments combine to shape health across the lifecourse. Using tools from genome science and longitudinal data frompopulation-based cohort studies and randomized trials, he aims to identifytargets for policy and clinical interventions to promote positive developmentand extend healthspan. Dr. Belsky received his PhD in Health Policy &Management from the Gillings School of Public Health, University of NorthCarolina at Chapel Hill and completed his postdoctoral training at the Centerfor the Study of Aging and Human Development, Duke University Medical Center.

‍

Cansu Canca is a philosopher andthe Founder and Director of AI Ethics Lab, one of the firstorganizations dedicated exclusively to practical and research-based AIethics consulting. She also serves as the Director of Responsible AIPractice at Northeastern University’s Institute for Experiential AI and asa Research Associate Professor of Philosophy, with affiliations to theEthics Institute and the DATA Initiative. Leading a multidisciplinary team ofcomputer scientists, philosophers, and legal scholars, she integrates ethicalanalysis into AI innovation and helps organizations design and implementresponsible AI governance strategies.

With aPh.D. in philosophy specializing in applied ethics, Cansu advisesFortune 500 companies and global institutions including the World EconomicForum, UNICRI, and INTERPOL on AI ethics and governance. Afounding editor of AI & Ethics (Springer Nature) and Chair of the IEEEAI Ethics Experts Network Criteria Committee, she has delivered over 100talks worldwide, including at Harvard Business School and the U.S. Departmentof Justice. Recognized among the 100 Brilliant Women in AI Ethics and MozillaRise25 Change Agents, she is internationally regarded as a pioneering voicein the responsible development and application of artificial intelligence.

‍

I.Glenn Cohen is theJames A. Attwood and Leslie Williams Professor of Law, Deputy Dean, and FacultyDirector of the Petrie-Flom Center for Health Law Policy, Biotechnology, andBioethics at Harvard Law School. An elected member of the National Academy ofMedicine, he is a leading authority on the intersection of law, bioethics, andemerging technologies, including artificial intelligence. He directs the Projecton Precision Medicine, Artificial Intelligence, and the Law (PMAIL) and hasadvised the U.S. Senate, OECD, and Vice President Kamala Harris on medical AIand bioethics policy. Author of over 300 articles and 20 books, including BigData, Health Law, and Bioethics and Digital Health Care Outside ofTraditional Clinical Settings, his work has appeared in Science, JAMA,The New England Journal of Medicine, and The New York Times.

‍

VadimGladyshev is Professor of Medicine and Director, Center for Redox Medicine,Brigham and Women’s Hospital, Harvard Medical School, USA. Dr. Gladyshev’s labfocuses on studying aging, rejuvenation and lifespan control using acombination of experimental and computational approaches. He has published morethan 400 articles. Dr. Gladyshev is the recipient of NIH Pioneer,Transformative and Eureka awards and is an elected member of the NationalAcademy of Sciences, USA.

‍

Albert Higgins-Chen is an Assistant Professor in theDepartment of Psychiatry at Yale University where he is a principalinvestigator. During his MD/PhD training at the University of Michigan, heworked with C. elegans identifying genes regulating aging and longevity. He isa clinically trained psychiatrist and has applied aging biomarkers toinvestigate how mental health and treatment affect aging. He now develops newmethods for measuring the biological aging process and the effects of aginginterventions.

‍

Winn Hong is the North America Venture Manager atNokia Ventures and the Cofounder, President, and CEO of Mesencyte Inc. Withover 18 years of experience in high-tech innovation, entrepreneurship, andleadership, he has successfully guided ventures across biotechnology, medicaldevices, alternative fuel, and digital technology. A Fellow of the AmericanInstitute for Medical and Biological Engineering, he has held key rolesincluding Deputy Executive Director at the Alfred E. Mann Institute forBiomedical Engineering at USC and Senior Technology Strategist at UCLA’sInstitute for Technology Advancement.

Earlier in his career, Hong worked at NASA’s JetPropulsion Laboratory, contributing to the design and testing of advancedsensors for military, medical, and space applications. He later served as COOof Sega.com, Ltd. and Principal at Convergent Ventures, managing early-stageinvestments in life sciences and technology. He holds an MBA from theUniversity of Chicago, an MS in Mechanical Engineering, and a BS in AerospaceEngineering from UCLA.

‍

Anand Iyer isthe Chief AI Officer at Welldoc,a global leader in digital health innovation. A pioneer in the integration of artificial intelligence, digitaltherapeutics, and mobile health, he played a central role in developing BlueStar®, the first FDA-cleareddigital therapeutic for adults with type 2 diabetes. Since joining Welldoc in2008, he has served in multiple leadership roles, including President, COO, andChief Strategy Officer, and was named MarylandHealthcare Innovator of the Year as well as one of Constellation Research’s Global AI 150Thought Leaders.

With acareer spanning technology, strategy, and regulatory policy, Iyer previously directed PRTM’swireless consulting practice, helping global firms harness disruptivetechnologies and new business models. He co-founded the Digital Therapeutics Alliance, founded the In-Building Wireless Alliance, and teaches advanced wirelesstechnologies to U.S. Department of Defense officers. He holds a Ph.D. and M.S. in Electrical and ComputerEngineering, an MBA fromCarnegie Mellon University, and a B.S. in Electrical and Computer Engineering from CarletonUniversity.

‍

SusannKeohane is theHead of Emerging AI Health Solutions, Ecosystem, and Innovation at IBM WatsonHealth and an IBM Master Inventor with over 200 patents issuedworldwide. Featured in Time Magazine, the BBC, and other global outlets,she is a recognized leader in applying artificial intelligence, machinelearning, and IoT to health innovation.

With morethan 15 years of experience leading cross-functional teams, Ms. Keohane hasheld roles as software engineer, consultant, researcher, and executive. Shepreviously served as IBM’s Global Leader for Healthy Aging and Global TechnicalLead for Accessibility Enablement, where she advanced enterprise-wideaccessibility and health technology initiatives. She also founded the IBM–UCSDCenter for Healthy Aging, driving groundbreaking collaborations that integrateAI and data-driven insights to improve health outcomes.

‍

Chaiwoo isa Research Scientist at the MIT AgeLab. She received her Ph.D. from theEngineering Systems Division at MIT. Her doctoral dissertation focused onidentifying factors of older adults’ technology adoption and incorporating theminto the user-centered design of technology-enabled products and services.Currently, her research employs a holistic framework that includes social andpsychological aspects, as well as physical and technical dimensions, in thedesign of technology systems.

Prior toworking at the AgeLab, she has participated in a number of industry-fundedprojects on usability testing, kansei engineering, and user behavioranalysis. She received her M.S. and B.S. from the Department of IndustrialEngineering at Seoul National University, Korea.

‍

As thehead of Digital Health, Hon Pak, M.D leads the Global Digital Health Strategyand Team. His focus is to leverage Samsung’s digital footprint across multipledevices and its strength in consumer experience to transform this consumerexperience into patient engagement to improve outcomes. Prior to joiningSamsung, Dr. Pak served as Chief Medical Officer for 3M HIS where he led theclinical economics research group, which developed content that is being usedboth payment and measuring outcomes for healthcare systems across the globe. Hehas experience in mobile health, telemedicine, and health IT in variouscapacity to include as a researcher, board member, CEO and CMO. He served inthe US military for 26 years, and he was the Army’s first Chief MedicalInformation Officer and physician Chief Information Officer for the U.S. ArmyMedical Department (AMEDD). He is a past board member and past president of theAmerican Telemedicine Association, and he currently serves on the editorialboard for Telemedicine and eHealth and on the Consumer Technology AssociationHealth Board.

Bio missing

Alex Zhavoronkov is the Founder and CEO of InsilicoMedicine, a global leader in generative artificial intelligence for drugdiscovery and biomarker development. Recognized by Deep Knowledge Analyticsas one of the world’s top 100 AI leaders in healthcare and named a ClarivateGlobal Highly Cited Scientist, he has pioneered the use of GenerativeAdversarial Networks (GANs) and Reinforcement Learning (RL) in drugdiscovery, enabling the identification of novel targets and the generation ofnew therapeutic molecules.

With abackground spanning biomedicine and computer science, Zhavoronkov hasheld senior roles at ATI Technologies, NeuroG, and the Biogerontology ResearchFoundation. Since founding Insilico in 2014, he has published over 200peer-reviewed papers and three books and serves on editorial boards including Trendsin Molecular Medicine and Frontiers in Genetics. He also co-chairsthe Annual Aging Research, Drug Discovery, and AI Forum and is an adjunctprofessor of artificial intelligence at the Buck Institute for Research onAging.

‍